التفاصيل البيبلوغرافية
| العنوان: |
康艾注射液辅助化疗治疗中晚期妇科生殖系统 恶性肿瘤的 Meta 分析. (Chinese) |
| Alternate Title: |
Meta-Analysis on Kang ’ ai Injection Combined with Chemotherapy in the Treatment of Intermediate and Advanced Gynecological Reproductive System Malignant Tumors. (English) |
| المؤلفون: |
郭 静, 杨玉晴, 李春晓, 陈玉欢, 凌 霄, 张莹莹 |
| المصدر: |
Evaluation & Analysis of Drug-Use in Hospitals of China / Zhongguo Yiyuan Yongyao Pingjia yu Fenxi; 2024, Vol. 24 Issue 12, p1501-1507, 7p |
| مصطلحات موضوعية: |
DRUG side effects, GENITALIA, ENDOMETRIAL cancer, LEUKOCYTE count, OVARIAN cancer, INTRAVENOUS drug abusers |
| Abstract (English): |
OBJECTIVE: To systematically evaluate the efficacy and safety of Kang’ ai injection combined with chemotherapy in the treatment of intermediate and advanced gynecological reproductive system malignant tumors. METHODS: CNKI, Wanfang Data, VIP, SinoMed, EI, Embase, PubMed and the Cochrane Library databases were retrieved to collect the randomized controlled trials (RCT) of Kang’ ai injection combined with chemotherapy in the treatment of intermediate and advanced gynecological reproductive system malignant tumors (cervical cancer, ovarian cancer, and endometrial cancer). The retrieval time was from the establishment of the database to Jun. 2023. After literature screening, data extraction and quality evaluation, R software was used for Meta-analysis. RESULTS: A total of 23 studies were enrolled, including 1 869 patients (942 in the study group and 927 in the control group). Meta-analysis showed that compared with conventional chemotherapy alone, Kang’ ai injection on the basis of conventional chemotherapy in the treatment of patients with intermediate and advanced gynecological reproductive system malignant tumors could significantly improve the objective remission rate (RR = 1. 37,95%CI = 1. 27-1. 48,P<0. 000 1), disease control rate (RR = 1. 20,95%CI = 1. 14-1. 26,P<0. 000 1), improvement rate of quality of life (RR = 1. 20,95%CI = 1. 13-1. 27,P<0. 000 1), significantly increase the level of immune function indicators (CD3 + :SMD= 2. 17,95%CI = 1. 10-3. 25,P<0. 000 1;CD4 + :SMD = 1. 74,95% CI = 0. 69-2. 79,P = 0. 001 2;CD8 + :SMD = 1. 01,95% CI = 0. 11- 1. 91,P = 0. 028 4;CD4 + / CD8 + :SMD= 1. 58,95%CI = 0. 85-2. 31,P<0. 000 1), significantly reduce the incidence of adverse drug reactions ( gastrointestinal adverse drug reactions: RR = 0. 53, 95% CI = 0. 39-0. 74, P = 0. 000 2; decreased leukocyte count: RR = 0. 52,95%CI = 0. 44-0. 61,P<0. 000 1; liver and kidney function injury: RR = 0. 69, 95%CI = 0. 50-0. 95,P = 0. 023 6), the differences were statistically significant. CONCLUSIONS: Current evidence shows that Kang’ai injection combined with chemotherapy can improve the clinical efficacy of patients with intermediate and advanced gynecological reproductive system malignant tumors, improve the immune function, reduce the occurrence of adverse drug reactions during chemotherapy, and play a role in enhancing efficiency and reducing toxicity. [ABSTRACT FROM AUTHOR] |
| Abstract (Chinese): |
目的:系统评价康艾注射液辅助化疗治疗中晚期妇科生殖系统恶性肿瘤的有效性和安全性。 方法:检索中国知网、万方 数据库、维普数据库、中国生物医学文献服务系统、EI、Embase、PubMed 及 the Cochranelibrary 等 8 个数据库中所有康艾注射液联合 化疗治疗中晚期妇科生殖系统恶性肿瘤 (宫颈癌、卵巢癌、子宫内膜癌)的随机对照试验 (RCT), 时间为建库至 2023 年 6 月。 筛选 文献、提取资料并进行质量评价后, 采用 R 软件进行 Meta 分析。 结果:纳入 23 篇文献, 共涉及 1 869 例患者 (研究组 942 例, 对照 组 927 例)。 Meta 分析结果显示, 与单纯常规化疗比较, 在常规化疗基础上联合应用康艾注射液治疗中晚期妇科生殖系统恶性肿 瘤患者, 能显著提高客观缓解率 (RR = 1. 37, 95%CI = 1. 27 ~ 1. 48, P<0. 000 1)、疾病控制率 (RR = 1. 20, 95%CI = 1. 14 ~ 1. 26, P< 0. 000 1)和生活质量改善率 (RR = 1. 20, 95% CI = 1. 13 ~ 1. 27, P< 0. 000 1), 显著改善免疫功能指标水平 (CD3 + :SMD = 2. 17, 95%CI = 1. 10~ 3. 25, P<0. 000 1; CD4 + :SMD = 1. 74, 95%CI = 0. 69 ~ 2. 79, P = 0. 001 2; CD8 + :SMD = 1. 01, 95%CI = 0. 11 ~ 1. 91, P = 0. 028 4; CD4 + / CD8 + :SMD= 1. 58, 95% CI = 0. 85 ~ 2. 31, P< 0. 000 1), 显著降低不良反应发生率 (消化道不良反应:RR = 0. 53, 95%CI = 0. 39~ 0. 74, P= 0. 000 2; 白细胞计数降低:RR= 0. 52, 95%CI = 0. 44 ~ 0. 61, P<0. 000 1; 肝肾功能损伤:RR = 0. 69, 95%CI = 0. 50~ 0. 95, P= 0. 023 6), 上述差异均有统计学意义。 结论:当前的证据表明, 康艾注射液辅助化疗可以提高中晚期三大妇科生殖 系统恶性肿瘤患者的临床疗效, 提高机体免疫功能, 减少化疗期间不良反应的发生, 发挥增效减毒的作用。 [ABSTRACT FROM AUTHOR] |
|
Copyright of Evaluation & Analysis of Drug-Use in Hospitals of China / Zhongguo Yiyuan Yongyao Pingjia yu Fenxi is the property of Evaluation & Analysis of Drug-Use in Hospitals of China Editorial Board and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |